Short answer: if Teflaro’s key patents expire and there’s no other strong exclusivity protecting sales, AbbVie (or its successor owner) could see a material decline in Teflaro-branded revenue as generics enter. The exact impact depends on when patents expire, what other protections remain, and how doctors and hospitals treat the drug once generics are available. Because those details are market- and region-specific, the revenue effect can range from modest to substantial.
How to think about it and how to quantify
Key factors that determine impact
- Patent coverage and expiry timing
- Are there composition-of-matter patents, method-of-use patents, and formulation patents? When do the dominant ones lapse?
- Are there regulatory data protections or market exclusivities (e.g., pediatric exclusivity) that extend protection beyond patent expiry in major markets (US, EU, Japan)?
- Geographic footprint
- Expiry dates and protections vary by country. A drug can lose exclusivity in one region earlier than another.
- Market dynamics post-expiry
- Rate of generic entry (how many manufacturers, speed of uptake in hospitals/clinics).
- Price erosion for the branded product and for generics.
- Share of sales in hospital settings vs outpatient; hospital procurement can slow but not prevent generic penetration.
- Alternatives and portfolio effects
- Whether AbbVie has other antibiotics or infectious-disease products to offset revenue declines.
- Any potential line extensions, new indications, or new formulations that could extend revenue.
- Overall proportion of AbbVie’s revenue that Teflaro represents
- If Teflaro is a smaller component of the portfolio, the revenue hit to the company may be modest even if Teflaro’s branded sales decline sharply.
How to build a simple projection (what I’d do if you want a model)
1) Gather data
- Current Teflaro revenue by region (if available from AbbVie investor materials).
- Patent expiry dates by major markets (USPTO Orange Book for the US; EU/IP offices for the EU; Japanese patents, etc.).
- Any known data exclusivity or other protections remaining in key markets.
2) Create baseline and scenarios
- Baseline: no additional protection after expiry (generic competition begins immediately in the first year post-expiry).
- Scenarios: gradual erosion (e.g., 60–90% generic share by year 2 or 3 in the US; slower in some markets), different price/volume erosion assumptions.
- Consider a “best case” where some exclusivity or strong hospital-order dynamics slow erosion, and a “worst case” with rapid uptake of generics.
3) Apply to revenue
- Calculate annual branded revenue decline due to generics, and separately model any shift to generic sales (if you want to estimate total market revenue for Teflaro-containing products).
- Include a buffer for offsetting factors (new indications, pipeline products) if relevant.
4) Sensitivity analysis
- Vary key inputs (expiry dates, rate of generic penetration, price erosion) to see a range of possible outcomes.
5) Add considerations for the broader AbbVie portfolio
- If Teflaro revenue is a small share of total company revenue, the impact on overall earnings may be modest even with a sizable drop in Teflaro specifically.
If you’d like, I can help you build a simple editable model. If you can share:
- The latest publicly available Teflaro sales by market (or a rough global number),
- Any known expiry dates or protections still in force (US/EU/Japan),
- And a couple of scenarios you want to test (e.g., “US expiry in year X with rapid generic entry” vs “delayed entry due to exclusivity”),
I’ll sketch out a basic projection and show how the revenue could evolve under those assumptions. I can also guide you to where you can pull the patent and exclusivity data (e.g., USPTO Orange Book, EMA patents, company annual reports) if you want to assemble it yourself.